The Relation of Circulating Antipneumococcal Immune Substances to the Course of Lobar Pneumonia Iii. Injected Immune Substances (Antipneumococcus Serum, Types I and Ii)

Journal of Clinical Investigation - United States
doi 10.1172/jci100612
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

American Society for Clinical Investigation

Related search

Concentrated Antipneumococcal Serum in the Treatment of Lobar Pneumonia

BMJ
1931English

The Occurrence and Virulence of Pneumococci in the Circulating Blood During Lobar Pneumonia and the Susceptibility of Pneumococcus Strains to Univalent Antipneumococcus Serum

Journal of Experimental Medicine
MedicineAllergyImmunology
1912English

Purification of Transfer Factor of Immune Sensibilization to Staphylococcal Antigen Substances

Biopolymers and Cell
BiochemistryGeneticsMolecular Biology
2000English

The Standardization of Antipneumococcic Serum Types I and Ii

Journal of Experimental Medicine
MedicineAllergyImmunology
1930English

The Protective Action of Type I Antipneumococcus Serum in Mice: Iii. The Significance of Certain Host Factors

Journal of Experimental Medicine
MedicineAllergyImmunology
1935English

Studies on Experimental Pneumonia: Vii. Treatment of Experimental Pneumococcus Type I Pneumonia in Monkeys With Type I Antipneumococcus Serum.

Journal of Experimental Medicine
MedicineAllergyImmunology
1920English

Studies on Circulating Immune Complexes: Iii. Factors Governing the Ability of Circulating Complexes to Localize in Blood Vessels

Journal of Experimental Medicine
MedicineAllergyImmunology
1968English

Treatment of Lobar Pneumonia by Anti-Pneumococcal Serum

BMJ
1932English

Table 3: Circulating Immune Cells as a Percentage of the Total PBMC in Stage II/III LCC and RCC.

English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy